Ndukwe Kizito C, Adebiyi Emmanuel K, Ugboko Vincent I, Adeyemo Wasiu L, Ajayi Folake O, Ladeinde Akin L, Okojie Victoria N, Ajike Sunday O, Olasoji Hector O
Faculty of Dentistry, Obafemi Awolowo University, Ile-Ife, Nigeria.
J Oral Maxillofac Surg. 2010 Sep;68(9):2111-4. doi: 10.1016/j.joms.2009.09.028. Epub 2010 Jun 11.
To obtain a national profile on the prevalence and management of ameloblastic carcinoma in Nigerians.
Data were collected from the case files of patients with a histologic diagnosis of ameloblastic carcinoma from 4 tertiary referral centers in Nigeria from January 1980 to December 2008.
Twenty patients were seen within the study period. There were 11 male and 9 female patients, with a male-to-female ratio of 1.2:1. Their ages ranged from 16 to 85 years (mean +/- SD, 41.63 +/- 19.8 years). The duration of the lesion before presentation was 6 months to 4 years. Twelve cases occurred in the posterior mandible alone, 1 case occurred in the anterior mandible alone, and 4 cases involved the anterior and posterior mandible. The posterior part of the maxilla was involved in 3 cases. A majority of the cases (17) occurred de novo, and 3 patients presented with carcinoma ex-ameloblastoma. Treatment included surgical resection with or without neck dissection. Eight patients declined treatment after diagnosis. Surgery was planned for 12 patients, but 2 patients died of intractable bleeding episodes before surgery. Mandibulectomies and maxillectomies were performed for 10 patients. Follow-up was carried out for 5 patients. Recurrence ranged from 6 to 96 months after the first surgery. Overall deaths recorded involved 6 patients. Three patients died within 3 years after the initial surgery and 1 patient died about 8 years after the initial surgery. One patient is still alive and well 1 year after surgery.
Ameloblastic carcinoma is an uncommon malignancy. Most cases occur in the mandible and arise de novo. Early diagnosis and radical local excision remain the mainstay of treatment.
获取尼日利亚成釉细胞癌患病率及治疗情况的全国性概况。
收集1980年1月至2008年12月期间尼日利亚4家三级转诊中心组织学诊断为成釉细胞癌患者的病例档案数据。
研究期间共诊治20例患者。其中男性11例，女性9例，男女比例为1.2:1。年龄范围为16至85岁（平均±标准差，41.63±19.8岁）。病变出现至就诊的时间为6个月至4年。仅下颌骨后部发生12例，仅下颌骨前部发生1例，下颌骨前后部均受累4例。上颌骨后部受累3例。大多数病例（17例）为原发性，3例患者为成釉细胞瘤恶变。治疗方法包括手术切除，可联合或不联合颈部清扫术。8例患者诊断后拒绝治疗。计划对12例患者进行手术，但2例患者在手术前死于难以控制的出血。对10例患者实施了下颌骨切除术和上颌骨切除术。对5例患者进行了随访。首次手术后复发时间为6至96个月。记录的总死亡病例为6例。3例患者在初次手术后3年内死亡，1例患者在初次手术后约8年死亡。1例患者术后1年仍存活且状况良好。
成釉细胞癌是一种罕见的恶性肿瘤。大多数病例发生在下颌骨，且为原发性。早期诊断和根治性局部切除仍是主要治疗方法。
